A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...

Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

The new trial focused on patients with advanced, stage 3 or 4 clear cell renal [kidney] cell carcinoma (ccRCC).

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug called Pembrolizumab (Keytruda).